Date: 2015-02-05
Type of information: Initiation of the trial
phase: 1-2
Announcement:
Company: Vivolux (USA - Sweden)
Product: VLX1570 and dexamethasone
Action
mechanism: proteasome inhibitor
Disease: multiple myeloma
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: This is a phase 1/2 single arm study to determine the safety and efficacy of VLX1570 IV infusion administered with low dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. (NCT02372240)
Latest
news:
